Jürg Bernhard
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol 2021; 80:306-315.
14.06.2021Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
14.06.2021Eur Urol 2021; 80:306-315
Ghadjar Pirus, Zaugg Kathrin, Guckenberger Matthias, Ost Piet, Reuter Christiane, Bosetti Davide G, Kaouthar Khanfir, Gomez Silvia, Wust Peter, Thalmann George N, Aebersold Daniel M, Sumila Marcin, Schär Corinne, Hayoz Stefanie, Bernhard Jürg, Zwahlen Daniel R, Hölscher Tobias, Gut Philipp, Polat Bülent, Hildebrandt Guido, Müller Arndt-Christian, Plasswilm Ludwig, Papachristofilou Alexandros, Swiss Group for Clinical Cancer Research (SAKK)
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
17.11.2017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
17.11.2017Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
Ghadjar P, Thalmann G, Aebersold D, Wust P, Biaggi Rudolf C, Dal Pra A, Schär C, Papachristofilou A, Putora P, Müller A, Hildebrandt G, Polat B, Gut P, Hölscher T, Stein J, Zwahlen D, Bernhard J, Hayoz S, Swiss Group for Clinical Cancer Research (SAKK). Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiother Oncol 2017
03.11.2017Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10
03.11.2017Radiother Oncol 2017
Ghadjar Pirus, Thalmann George N, Aebersold Daniel M, Wust Peter, Biaggi Rudolf Christine, Dal Pra Alan, Schär Corinne, Papachristofilou Alexandros, Putora Paul Martin, Müller Arndt-Christian, Hildebrandt Guido, Polat Bülent, Gut Philipp, Hölscher Tobias, Stein Jürgen, Zwahlen Daniel R, Bernhard Jürg, Hayoz Stefanie, Swiss Group for Clinical Cancer Research (SAKK)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
10.10.2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
10.10.2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
25.07.2016Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
25.07.2016Prostate 2016; 76:1519-1527
Cathomas Richard, Gillessen Sommer Silke, Manetsch Gabriela, Bernhard Jürg, Mohaupt Markus G, Roggero Enrico, Rauch Daniel, Vilei Simona Berardi, Hayoz Stefanie, Kenner Heike, von Burg Philippe, Elliott Tony, Rothermundt Christian, Winterhalder Ralph, Mark Michael, Crabb Simon J, Swiss Group for Clinical Cancer Research SAKK
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 2016; 34:1601-10.
28.03.2016Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
28.03.2016J Clin Oncol 2016; 34:1601-10
Ribi Karin, Torres Roberto, Lombardi Davide, Puglisi Fabio, Karlsson Per, Ruhstaller Thomas, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Price Karen N, Gelber Richard D, Regan Meredith M, Neven Patrick, Perelló Antonia, Kerbrat Pierre, Luo Weixiu, Bernhard Jürg, Francis Prudence A, Burstein Harold J, Ciruelos Eva, Bellet Meritxell, Pavesi Lorenzo, Lluch Ana, Visini Marilena, Parmar Vani, Tondini Carlo, Fleming Gini F
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58.
16.06.2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
16.06.2015Lancet Oncol 2015; 16:848-58
Bernhard Jürg, Regan Meredith M, Pagani Olivia, Fleming Gini F, Francis Prudence A, Price Karen N, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Parmar Vani, Pavesi Lorenzo, Puglisi Fabio, Luo Weixiu, Ribi Karin, Colleoni Marco, Burstein Harold J, Tondini Carlo, Pinotti Graziella, Spazzapan Simon, Ruhstaller Thomas, Walley Barbara A
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
01.06.2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
01.06.2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65:3096-106.
01.12.2013Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
01.12.2013Arthritis Rheum 2013; 65:3096-106
Ciurea Adrian, Weber Ulrich, Boonen Annelies, Dougados Maxime, van der Heijde Désirée, Michel Beat A, Nissen Michael J, Müller Rüdiger, Weiss Bettina, Tamborrini Giorgio, Rufibach Kaspar, Stekhoven Daniel, Kissling Rudolf, Beyeler Brigitte, Dudler Jean, Bernhard Jürg, Exer Pascale, Scherer Almut, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2011; 48:377-84.
15.11.2011Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
15.11.2011Eur J Cancer 2011; 48:377-84
Pesce Gianfranco A, Bernhard Jürg, Kotrubczik Nina M, D'Addario Giannicola, Pilop Christiane, Weber Damien C, Bodis Stephan, Pless Miklos, Mayer Michael, Cathomas Richard, Peters Solange, Klingbiel Dirk, Ribi Karin, Zouhair Abderahim, von Moos Roger, Schlaeppi Marc, Caspar Clemens B, Fischer Natalie, Anchisi Sandro, Stupp Roger
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Sun Z, Ribi K, Aldridge J, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010
03.11.2010Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
03.11.2010Breast Cancer Res Treat 2010
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Sun Zhuoxin, Ribi Karin, Aldridge Julie, Bernhard Jürg
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Stephens A, Sun Z, Ribi K, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19:388-95.
10.04.2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
10.04.2010Breast 2010; 19:388-95
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Stephens Alisa, Sun Zhuoxin, Ribi Karin, Bernhard Jürg
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörger M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
01.09.2008Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
01.09.2008Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404
Ribi Karin, Stahel Rolf A, Ris Hans-Beat, Stupp Roger, Schmid Ralph A, Betticher Daniel, Jörger Markus, Bodis Stephan, Weder Walter, Schuller Jan C, Bernhard Jürg, Swiss Group for Clinical Cancer Research SAKK
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701.
01.08.2008Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701
Bernhard Jürg, Pestalozzi Bernhard C, Köhne Claus-Henning, Mingrone Walter, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Koeberle Dieter, Herrmann Richard, Figer Arie, Bauer Jean, Saletti Piercarlo, Dietrich Daniel, Scheithauer Werner, Gerber Daniela, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Central European Cooperative Oncology Group
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Roth A, de Braud F, Seymour M, Widmer L, Glynne-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23.
01.08.2007Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
01.08.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:3217-23
Roth Arnaud D, de Braud Filippo, Seymour Matthew, Widmer Lukas, Glynne-Jones Robert, Leslie Martin, Wernli Martin, Maibach Rudolf, Rufibach Kaspar, Borner Markus M, Köberle Dieter, Saletti Piercarlo, Bernhard Jürg, Falk Stephen, Stupp Roger, Fazio Nicola, Swiss Group for Clinical Cancer Research
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann R, Stemmer S, Tàmas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7.
01.06.2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
01.06.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7
Herrmann Richard, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Köberle Dieter, Cina Susanne, Bernhard Jürg, Dietrich Daniel, Scheithauer Werner, Swiss Group for Clinical Cancer Research, Mingrone Walter, Köhne Claus-Henning, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Saletti Piercarlo, Bauer Jean, Figer Arie, Pestalozzi Bernhard, Central European Cooperative Oncology Group
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.
20.01.2007Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
20.01.2007JCO 2007; 25:263-70
Bernhard Jürg, Coates Alan S, Goldhirsch Aron, Price Karen N, Thürlimann Beat, Aebi Stefan, Collins John, Murray Elizabeth, Forbes John F, Gelber Richard D, Hürny Christoph, Castiglione-Gertsch Monica, Zahrieh David, International Breast Cancer Study Group Trial VIII
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
01.09.2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
01.09.2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)